SEC Tracker
Get the app

Passage BIO PASG

Passage BIO reported a net loss of $4.72 million

Passage BIO (PASG) filed a 10-Q with the SEC on Nov 10, 2026, 7:16 am ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Net loss: $4.72 million for the three months ended Sep 30, 2026
  2. Diluted EPS: -$1.47 for the three months ended Sep 30, 2026
  3. Cash and equivalents: $20.16 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Going-concern warning repeated

“As a result of these factors, there is substantial doubt about our ability to continue as a going concern within one year after the date the interim consolidated financial statements included in this Quarterly Report on Form 10-Q are issued.”
In MD&A. Read it in the filing 10-Q on EDGAR

Also in the prior 10-Q (filed Aug 10, 2026). Prior report Prior on EDGAR

Quoted from the filing.

Get an email when Passage BIO files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

No new risk factors or legal mentions.

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Operating income and margin−$4.94M−$8.27M+40%
Net income−$4.72M−$7.82M+40%
Operating cash flow−$4M−$9.18M+57%
Cash$20.16M$24.16M−17%

Data on this page was fetched . The filing on SEC.gov is the record.